Literature DB >> 9472300

Wuchereria bancrofti in Tanzania: microfilarial periodicity and effect of blood sampling time on microfilarial intensities.

P E Simonsen1, L Niemann, D W Meyrowitsch.   

Abstract

The circadian periodicity of Wuchereria bancrofti microfilarial (mf) intensities in peripheral blood was analysed in a group of infected individuals from an endemic community in north-eastern Tanzania. The mf density was quantified at two-hourly intervals for 24 hours. A clear nocturnal periodic pattern was observed. Mathematical analysis of the data indicated a peak at 0152 h and a periodicity index of 117.5. A periodicity equation was developed describing the average relation between mf intensity and hour of the day for the study area. Based on the observed periodicity pattern, the effect of blood sampling before peak time is discussed, and the importance of taking sampling time into consideration when analysing data from epidemiological studies is emphasized. A simple method is devised which can be used to adjust for the influence of time on mf intensities, in studies where accurate information on mf intensities is necessary, and where it is impossible to obtain all samples at peak time.

Mesh:

Year:  1997        PMID: 9472300     DOI: 10.1046/j.1365-3156.1997.d01-237.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  8 in total

1.  Analysis of the 24-h microfilarial periodicity of Mansonella perstans.

Authors:  Santa Maria Asio; Paul E Simonsen; Ambrose W Onapa
Journal:  Parasitol Res       Date:  2008-12-24       Impact factor: 2.289

2.  Lymphatic filariasis control in Tanzania: effect of repeated mass drug administration with ivermectin and albendazole on infection and transmission.

Authors:  Paul E Simonsen; Erling M Pedersen; Rwehumbiza T Rwegoshora; Mwelecele N Malecela; Yahya A Derua; Stephen M Magesa
Journal:  PLoS Negl Trop Dis       Date:  2010-06-01

3.  Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis.

Authors:  Cara L Macfarlane; Shyam S Budhathoki; Samuel Johnson; Marty Richardson; Paul Garner
Journal:  Cochrane Database Syst Rev       Date:  2019-01-08

4.  Mapping of Bancroftian Filariasis in Cameroon: Prospects for Elimination.

Authors:  Hugues C Nana-Djeunga; Jules B Tchatchueng-Mbougua; Jean Bopda; Steve Mbickmen-Tchana; Nathalie Elong-Kana; Etienne Nnomzo'o; Julie Akame; Ann Tarini; Yaobi Zhang; Flobert Njiokou; Joseph Kamgno
Journal:  PLoS Negl Trop Dis       Date:  2015-09-09

5.  Lymphatic filariasis control in Tanga Region, Tanzania: status after eight rounds of mass drug administration.

Authors:  Paul E Simonsen; Yahya A Derua; Stephen M Magesa; Erling M Pedersen; Anna-Sofie Stensgaard; Mwelecele N Malecela; William N Kisinza
Journal:  Parasit Vectors       Date:  2014-11-12       Impact factor: 3.876

6.  Loss of sensitivity of immunochromatographic test (ICT) for lymphatic filariasis diagnosis in low prevalence settings: consequence in the monitoring and evaluation procedures.

Authors:  Raceline Gounoue-Kamkumo; Hugues C Nana-Djeunga; Jean Bopda; Julie Akame; Ann Tarini; Joseph Kamgno
Journal:  BMC Infect Dis       Date:  2015-12-23       Impact factor: 3.090

7.  Lymphatic filariasis control in Tanzania: effect of six rounds of mass drug administration with ivermectin and albendazole on infection and transmission.

Authors:  Paul E Simonsen; Yahya A Derua; William N Kisinza; Stephen M Magesa; Mwele N Malecela; Erling M Pedersen
Journal:  BMC Infect Dis       Date:  2013-07-21       Impact factor: 3.090

8.  Community-based trial of annual versus biannual single-dose ivermectin plus albendazole against Wuchereria bancrofti infection in human and mosquito populations: study protocol for a cluster randomised controlled trial.

Authors:  Dziedzom K de Souza; Collins S Ahorlu; Susan Adu-Amankwah; Joseph Otchere; Sedzro K Mensah; Irene A Larbi; George E Mensah; Nana-Kwadwo Biritwum; Daniel A Boakye
Journal:  Trials       Date:  2017-10-02       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.